Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders

Expert Opinion on Drug Safety

Volumn 9, Issue 4, 2010, Pages 623-631

  Luykx, Jurjen J ^a   Carpay, Johannes A ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Tergooi Hospitals   (Netherlands)

Author keywords

adverse effect(s); neuromodulatory drug(s); neuropsychiatry; Side effect(s); topiramate

Indexed keywords

NALTREXONE; PLACEBO; TOPIRAMATE; FRUCTOSE; NEUROPROTECTIVE AGENT;

ADD ON THERAPY; ALCOHOLISM; BINGE EATING DISORDER; BORDERLINE STATE; BULIMIA; CLINICAL TRIAL; CONCENTRATION LOSS; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHASIA; EPILEPSY; ESSENTIAL TREMOR; FATIGUE; HUMAN; INSOMNIA; LOW BACK PAIN; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; MIGRAINE; MONOTHERAPY; NERVOUSNESS; NEUROPSYCHIATRY; PARESTHESIA; REVIEW; SIDE EFFECT; SOMNOLENCE; ANALOGS AND DERIVATIVES; BRAIN DISEASES; CHEMICALLY INDUCED; MENTAL DISORDERS; NEUROLOGIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BRAIN DISEASES; FRUCTOSE; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; PARESTHESIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953796076     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740331003739196     Document Type: Review

References (38)

1. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007;298(14):1641-1651
2. Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2006;26(1):61-66 (Pubitemid 43167093)
3. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005;57(5):495-499
4. Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004;65(11):1515-1519
5. Frima N, Grunewald RA. A double-blind, placebo-controlled, crossover trial of topiramate in essential tremor. Clin Neuropharmacol 2006;29(2):94-96
6. Ondo WG, Jankovic J, Connor GS, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006;66(5):672-677
7. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160(2):255-261
8. Van Ameringen M, Mancini C, Patterson B, Bennett M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006;23(1):1-5
9. Muehlbacher M, Nickel MK, Kettler C, et al. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain 2006;22(6):526-531
10. Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 2008;17(5):405-421
11. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291(8):965-973
12. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251(8):943-950
13. Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci 2004;25(5):245-250
14. Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther 2006;28(7):1002-1011
15. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61(4):490-495 (Pubitemid 38923736)
16. Silvestrini M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23(8):820-824
17. Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 2009;85(3):283-288
18. Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373(9682):2223-2233
19. WHO. Global Status report on Alcohol 2004. Geneva: World Health Organization 2004
20. Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008;103(12):2035-2044
21. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 2004;61(9):905-912
22. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003;361(9370):1677-1685
23. Johnson BA, Rosenthal N, Capece JA, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 2008;168(11):1188- 1199
24. Benito-Leon J, Louis ED. Essential tremor: emerging views of a common disorder. Nat Clin Pract Neurol 2006;2(12):666-678, quiz 2p following 91
25. Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002;59(1):132-134
26. Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol 2008;31(2):97-103
27. Galvez-Jimenez N, Hargreave M. Topiramate and essential tremor. Ann Neurol 2000;47(6):837-838
28. Lieb K, Zanarini MC, Schmahl C, et al. Borderline personality disorder. Lancet 2004;364(9432):453-461
29. Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007;68(9):1324-1332
30. McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007;61(9):1039-1048
31. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry 2004;65(11):1463-1469
32. Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003;64(12):1449-1454
33. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003;64(11):1335- 1341
34. Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005;38(4):295-300
35. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41(7):646-657
36. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005;6(6):429-440
37. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol 2007;27(6):677-681
38. Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005;59(8):961-968